aibio
Listings ·
Eledon holders approve raising authorized common shares to 450,000,000
The annual meeting on June 18, 2026 approved the increase from 300,000,000 shares. The amendment is effective June 22, 2026.
ELDN Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals (ELDN) news
Latest Eledon Pharmaceuticals news
- Financings
Eledon Pharmaceuticals swaps 4,203,764 shares for a pre-funded warrant with Coastlands
The exchange closed on December 30, 2025. The warrant has an initial exercise price of $0.001 per share.
Eledon Pharmaceuticals annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $66.3 million | $52.0 million |
| Net income (loss) | -$45.6 million | -$36.2 million |
| Cash from operations | -$62.3 million | -$47.3 million |
| Cash and equivalents | $22.8 million | $20.5 million |
| Short-term investments | $110.5 million | $119.6 million |
Questions about Eledon Pharmaceuticals
What is the ticker symbol of Eledon Pharmaceuticals?
Eledon Pharmaceuticals, Inc. trades under the ticker ELDN on NASDAQ.
Where is Eledon Pharmaceuticals listed?
Eledon Pharmaceuticals, Inc. is listed on NASDAQ. Our directory also records these other listings: LSX:A2QL00.
What is the SEC CIK of Eledon Pharmaceuticals?
The SEC Central Index Key (CIK) for Eledon Pharmaceuticals, Inc. is 1404281. Its filings are on SEC EDGAR.
How many shares does Eledon Pharmaceuticals have outstanding?
81,261,152 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-13.
Which country or territory is Eledon Pharmaceuticals listed under?
Our directory records Eledon Pharmaceuticals, Inc. under United States.
What does Eledon Pharmaceuticals do?
Our directory classifies Eledon Pharmaceuticals, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Eledon Pharmaceuticals?
The ISIN recorded for Eledon Pharmaceuticals, Inc. is US28617K1016.
Does aibio.space cover Eledon Pharmaceuticals?
aibio.space lists Eledon Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Eledon Pharmaceuticals incorporated?
SEC records list its state or country of incorporation as DE.
Is Eledon Pharmaceuticals profitable?
Eledon Pharmaceuticals, Inc. reported a net loss of $45.6 million for the fiscal year ended Dec 31, 2025, and used $62.3 million of cash in operations, per its annual report to the SEC.
How much does Eledon Pharmaceuticals spend on research and development?
$66.3 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Eledon Pharmaceuticals have?
$88.8 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
What is the latest Eledon Pharmaceuticals (ELDN) stock news?
Our latest story on Eledon Pharmaceuticals, dated Jun 22, 2026: "Eledon holders approve raising authorized common shares to 450,000,000". The annual meeting on June 18, 2026 approved the increase from 300,000,000 shares. The amendment is effective June 22, 2026. Source.
What is Eledon Pharmaceuticals's latest stock offering or financing news?
Our latest financing story, dated Jan 2, 2026: "Eledon Pharmaceuticals swaps 4,203,764 shares for a pre-funded warrant with Coastlands". The exchange closed on December 30, 2025. The warrant has an initial exercise price of $0.001 per share. Source.
Is Eledon Pharmaceuticals at risk of delisting?
Our latest listing story, dated Jun 22, 2026: "Eledon holders approve raising authorized common shares to 450,000,000". The annual meeting on June 18, 2026 approved the increase from 300,000,000 shares. The amendment is effective June 22, 2026. Source.
Investor discussion: Eledon Pharmaceuticals
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
- Listings
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.03,5.07,9.01). Source
- Financings
Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,9.01). Source
- Legal
Said earlier financial statements should no longer be relied on. SEC Form 8-K (Items 2.02,4.02,9.01). Source
- Listings
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.03,5.07,9.01). Source
- Legal
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Stock chart
SEC filings and registration
- SEC name
- Eledon Pharmaceuticals, Inc.
- CIK
- 1404281
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- ELDN (Nasdaq)
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Business address
- 19800 MACARTHUR BLVD., IRVINE, CA, 92612
- Phone
- 949-238-8090
- Shares outstanding
- 81,261,152 as of 2026-08-10 (10-Q filed 2026-08-13)
- Former names
- Eledon Pharmaceuticals, Inc.; Novus Therapeutics, Inc.; Tokai Pharmaceuticals Inc
Recent filings
Listing details
- Company
- Eledon Pharmaceuticals, Inc.
- Ticker
- ELDN
- Listing
- NASDAQ
- Country or territory
- United States
- Business scope
- Pharmaceuticals: Major
- ISIN
- US28617K1016
- Other listed symbols
- LSX:A2QL00
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction